NCT02353832 Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer Status COMPLETED Phase PHASE2
NCT02353819 Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02353715 Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing Status COMPLETED Phase N/A
NCT02349139 Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer Status TERMINATED Phase PHASE1
NCT02349022 Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy Status COMPLETED Phase PHASE2
NCT02346526 A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer Status COMPLETED Phase PHASE2
NCT02344017 Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT02342054 Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer Status UNKNOWN Phase PHASE2
NCT02341404 A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer Status COMPLETED Phase PHASE2
NCT02339701 Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer Status ACTIVE_NOT_RECRUITING Phase NA
NCT02339168 Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer Status COMPLETED Phase PHASE1
NCT02333435 Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02325557 ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) Status COMPLETED Phase PHASE1/PHASE2
NCT02324998 Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy Status COMPLETED Phase PHASE1
NCT02321358 Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors Status COMPLETED Phase NA